Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.57 |
| ▸ | CES1 | P23141 | 3/20 | 0.57 |
| ▸ | ACKR3 | P25106 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9827785 | 0.89 | CES2 (0.53) | CES2CES1ACKR3DRD2NPC1 | |
| Ethylene SCHEMBL10996445 | 0.86 | CES2 (0.50) | CES2CES1ACKR3DRD2NPC1 | |
| SCHEMBL2597507 | 0.85 | CES2 (0.61) | CES2CES1ACKR3DRD2NPC1 | |
| SCHEMBL23152719 | 0.83 | CES2 (0.59) | CES2CES1ACKR3DRD2NPC1 | |
| SCHEMBL3054837 | 0.82 | DGAT1 (0.56) | ACKR3NPC1RAB9A | |
| SCHEMBL6944180 | 0.81 | CES2 (0.57) | CES2CES1ACKR3 | |
| SCHEMBL11847285 | 0.81 | CES2 (0.57) | CES2CES1ACKR3DRD2NPC1 | |
| SCHEMBL31661842 | 0.81 | CES2 (0.57) | CES2CES1ACKR3DRD2 | |
| SCHEMBL3527017 | 0.81 | CES2 (0.57) | CES2CES1ACKR3DRD2 | |
| SCHEMBL10768717 | 0.80 | CHRNA7 (0.46) | CES2CES1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| EP-3019476-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | Syngenta Participations AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015003951-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-01-15 | — | — | WO | disclosed |
| US-7338949-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-04 | — | — | US | disclosed |
| US-7338949-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-04 | — | — | US | disclosed |
| US-20070082895-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082895-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | US | disclosed |
| US-6670363-B1 | 2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol -1-yl) propyl)-4-(4-(4-(4-chlorophenyl)-1-piperazinyl)phenyl) -3-(2H,4H)-1,2,4-triazolone; opportunistic fungal infections | RANBAXY LABORATORIES LIMITED (IN) | 2003-12-30 | — | — | US | disclosed |
| EP-1278755-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | Ranbaxy Laboratories, Limited (IN) | 2003-01-29 | — | — | EP | disclosed |
| EP-0871626-B1 | TRIAZOLONES AS APOLIPOPROTEIN-B SYNTHESIS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001066551-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | disclosed |
| US-6197972-B1 | CHEMICAL INTERMEDIATES FOR ANTICHOLESTEROL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-06 | — | — | US | disclosed |
| US-5922718-A | NOVEL ANTILIPEMIC COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | CES2 36/4885CES1 402/4885ACKR3 3980/4885 |
| US-20070082895-A1 | Novel mycobacterial inhibitors | HRH4, NAT1, CBR3 | CES2 2985/4885CES1 1415/4885ACKR3 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.